 |
|
NKF
K/DOQI GUIDELINES
|
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease
Tables
Figures
Acronyms
and Abbreviations
Algorithms
Work
Group Members
K/DOQI
Advisory Board Members
Foreword
Introduction
- Guideline
1: Evaluation of Calcium and Phosphorus Metabolism
- Guideline
2: Assessment of Bone Disease Associated with CKD
- Guideline
3: Surgical Management of Osteodystrophy
- Guideline
4: Target Serum Phosphorus Levels
- Guideline
5: Management of Dietary Phosphorus Intake in Children with CKD
- Guideline
6: Use of Phosphate Binders in CKD
- Guideline
7: Serum Calcium and Calcium-Phosphorus Product
- Guideline
8: Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients
- Guideline
9: Active Vitamin D Therapy in CKD Patients
- Guideline 9A: Active Vitamin D Therapy in CKD Patients with CKD Stages 2-4
- Guideline 9B: Active Vitamin D Therapy in Patients on Dialysis (CKD Stage 5)
- Guideline
10: Dialysate Calcium Concentrations
- Guideline
11: Recommendations for the Use of Growth Hormone for Children with CKD
- Guideline
12: Aluminum Overload and Toxicity in CKD
- Guideline
13: Treatment of Aluminum Toxicity
- Guideline
14: Treatment of Bone Disease in CKD
- Guideline 14A: Hyperparathyroid (High-Turnover) Bone Disease
- Guideline 14B: Rickets/Osteomalacia
- Guideline 14C: Adynamic Bone Disease
- Guideline
15: Parathyroidectomy in Patients with CKD
- Guideline
16: Metabolic Acidosis
- Guideline 17: Bone Disease in the Pediatric Kidney Transplant Recipient
Afterword
Biographical Sketches of Work Group Members
References
Disclaimer